Analyzing the clinical-pathological characteristics of HER-2 ultra-low breast cancer in a medium-sized Brazilian city: a brief communication

Autores

  • Tony Maronesi Bagio Faculdade de Medicina, Centro Universitário Católico Salesiano Auxilium (UNISALESIANO) https://orcid.org/0000-0002-9093-7125
  • Paulo Gil Katsuda Clínica Ginecológica Katsuda
  • Deolino João Camilo Júnior Instituto de Patologia de Araçatuba (IPAT)
  • José Cândido Caldeira Xavier Júnior Faculdade de Medicina, Centro Universitário Católico Salesiano Auxilium e Instituto de Patologia de Araçatuba (IPAT) https://orcid.org/0000-0003-0503-419X

DOI:

https://doi.org/10.34019/1982-8047.2023.v49.42185

Palavras-chave:

Neoplasias da Mama, Genes erbB-2, Antígeno Ki-67, Receptores de Estrogênio

Resumo

N/A

Downloads

Não há dados estatísticos.

Referências

Instituto Nacional de Câncer (BR). Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2022 [acesso em 2023 jul 12]. Disponível em: https:// www.inca.gov.br/sites/ufu.sti.inca.local/files//media/ document//estimativa-2023.pdf

Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. DOI: 10.3322/caac.21660

Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. DOI: 10.1093/annonc/mdt303

Shi J, Zhang L, Geng C et al. Her-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study. Frontiers in Oncology. 2023; 13:1-9. DOI: 10.3389/fonc.2023.1210314

Giordano SH, Franzoi MAB, Temin S et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022; 40(23):2612-35. DOI: 10.1200/jco.22.00519

Venetis K, Crimini E, Sajjadi E et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci. 2022; 9:834651. DOI:10.3389/fmolb.2022.834651

Tuluhong D, Li X, Gao H et al. Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy. Eur J Cancer Prev. 2023; 32(4):377-87. DOI: 10.1097/CEJ.0000000000000813

Chen Z, Jia H, Zhang H, et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Research and Treatment. 2023; 202(2):313-23. DOI: 10.1007/s10549-023-07079-8

Allison K, Hammond M, Dowsett M et.al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020; 38(12):1346-66. DOI: 10.1200/jco.19.02309

Finkelman B, Zhang H, Hicks D et al. The evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers. 2023; 15(3):808. DOI: 10.3390/cancers15030808

Lakhani SR, Ellis IO, Schnitt SJ et al. World Health Organization classification of tumours of the breast. 4th. ed. Lyon: IARC Press; 2012.

Downloads

Publicado

2024-01-29

Como Citar

1.
Maronesi Bagio T, Katsuda PG, Camilo Júnior DJ, Xavier Júnior JCC. Analyzing the clinical-pathological characteristics of HER-2 ultra-low breast cancer in a medium-sized Brazilian city: a brief communication. HU Rev [Internet]. 29º de janeiro de 2024 [citado 19º de maio de 2024];49:1-3. Disponível em: https://periodicos.ufjf.br/index.php/hurevista/article/view/42185

Edição

Seção

Comunicação breve